Nintedanib (Vargatef®)

Assessment Status Assessment Process Complete
Drug Nintedanib
Brand Vargatef®
Indication Is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy.
Assessment Process
Rapid review commissioned 02/01/2015
Rapid review completed 10/02/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 03/06/2015
Preliminary review sent to Applicant 25/03/2016
NCPE assessment outcome Reimbursement Not Recommended at the Submitted Price.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations February 2017.